S Zeuzem

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
    Stefan Zeuzem
    University Hospital, JW Goethe University, Frankfurt, Germany
    Hepatology 55:749-58. 2012
  2. ncbi Telaprevir for the treatment of hepatitis C
    Nicole Forestier
    J W Goethe University Hospital, Department of Medicine, 1, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Expert Opin Pharmacother 13:593-606. 2012
  3. ncbi Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    Stefan Zeuzem
    J W Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 141:2047-55; quiz e14. 2011
  4. ncbi Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
  5. ncbi HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
    Nikolai Mühlberger
    Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, UMIT University of Health Sciences, Medical Informatics and Technology, Hall iT, Austria
    BMC Public Health 9:34. 2009
  6. ncbi Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Mireen Friedrich-Rust
    Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany
    BMC Gastroenterol 10:103. 2010
  7. ncbi Expert opinion on the treatment of patients with chronic hepatitis C
    S Zeuzem
    Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    J Viral Hepat 16:75-90. 2009
  8. ncbi Interleukin-12 in the treatment of chronic hepatitis B and C
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Antiviral Res 52:181-8. 2001
  9. ncbi The kinetics of hepatitis C virus infection
    S Zeuzem
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Frankfurt a M, Germany
    Clin Liver Dis 5:917-30. 2001
  10. ncbi Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
    Stefan Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt a Main, Germany
    J Hepatol 51:11-20. 2009

Detail Information

Publications132 found, 100 shown here

  1. ncbi The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
    Stefan Zeuzem
    University Hospital, JW Goethe University, Frankfurt, Germany
    Hepatology 55:749-58. 2012
    ..Transient elevations in serum bilirubin occurred in all treatment groups. CONCLUSION: In genotype 1 HCV, adding RBV or RBV with Peg-IFN provides additive antiviral activity to combination therapy with tegobuvir and GS-9256...
  2. ncbi Telaprevir for the treatment of hepatitis C
    Nicole Forestier
    J W Goethe University Hospital, Department of Medicine, 1, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Expert Opin Pharmacother 13:593-606. 2012
    ..At present, there are several next-generation DAAs in clinical development in combination with Peg-IFN-?. The future, however, may also include new treatment strategies, such as oral DAA combinations...
  3. ncbi Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    Stefan Zeuzem
    J W Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 141:2047-55; quiz e14. 2011
    ..We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI 207127 (an inhibitor of the NS5B non-nucleoside polymerase) with ribavirin...
  4. ncbi Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
    ..These mutations are located in the protein interior and far away from the ligand binding pocket...
  5. ncbi HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
    Nikolai Mühlberger
    Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, UMIT University of Health Sciences, Medical Informatics and Technology, Hall iT, Austria
    BMC Public Health 9:34. 2009
    ..We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed...
  6. ncbi Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Mireen Friedrich-Rust
    Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany
    BMC Gastroenterol 10:103. 2010
    ..While a systematic review has shown comparable results for both individual markers, there has been no direct comparison of both markers...
  7. ncbi Expert opinion on the treatment of patients with chronic hepatitis C
    S Zeuzem
    Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    J Viral Hepat 16:75-90. 2009
    ....
  8. ncbi Interleukin-12 in the treatment of chronic hepatitis B and C
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Antiviral Res 52:181-8. 2001
    ..5 microg/kg dose group. In conclusion, antiviral activity of rHuIL-12 in patients with chronic hepatitis B or C does not appear to be advantageous in comparison to other currently available treatments...
  9. ncbi The kinetics of hepatitis C virus infection
    S Zeuzem
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Frankfurt a M, Germany
    Clin Liver Dis 5:917-30. 2001
    ..Nonresponding patients typically show constant viremia or even a rebound during this second phase...
  10. ncbi Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
    Stefan Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt a Main, Germany
    J Hepatol 51:11-20. 2009
    ..In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2 years. We analyzed all telbivudine recipients in this trial to determine the predictors of optimal outcomes...
  11. ncbi [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response]
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt Main
    MMW Fortschr Med 144:30-4. 2002
    ..In the meantime, concrete treatment recommendations are available for every genetic type of HCV, for patients experiencing relapse, and for primary treatment failures...
  12. ncbi Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590 Frankfurt a M, Germany
    Expert Opin Investig Drugs 10:2201-13. 2001
    ..The advantages of PEG-IFN alfa-2a were also seen in patients with cirrhosis or hepatitis C virus (HCV) genotype 1...
  13. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
    ..Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin...
  14. ncbi Albinterferon Alfa-2b was not inferior to pegylated interferon-? in a randomized trial of patients with chronic hepatitis C virus genotype 1
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 139:1257-66. 2010
    ..We evaluated the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFN?-2b...
  15. ncbi Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response
    Stefan Zeuzem
    Department of Medicine I, J W Goethe University Hospital, Frankfurt, Germany
    Curr Med Res Opin 26:1733-43. 2010
    ..However, recent studies have shown that on-treatment markers of virologic response can be used to tailor treatment duration according to each patient's response to therapy...
  16. ncbi Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 13:747-60. 2008
    ..The treatment paradigm for chronic hepatitis C continues to evolve and will eventually incorporate new drugs as they are approved...
  17. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C...
  18. ncbi Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
    ..1 versus 4.3 days; P = 0.006). CONCLUSION: Alb-IFN administered q2wk or q4wk may offer comparable efficacy, with an improved dosing schedule, compared with PEG-IFNalpha-2a...
  19. ncbi Gut-liver axis
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt a M, Germany
    Int J Colorectal Dis 15:59-82. 2000
    ..Furthermore, the liver is the primary organ for metastasis of intestinal cancer. Many viral, bacterial, fungal, and parasitic diseases affect the intestine as well as the liver and the biliary tract...
  20. ncbi Interferon-based therapy for chronic hepatitis C: current and future perspectives
    Stefan Zeuzem
    Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany
    Nat Clin Pract Gastroenterol Hepatol 5:610-22. 2008
    ..These compounds will be used, at least initially, in combination with peginterferon alpha plus ribavirin, extending the pivotal role of interferon-based therapy in the management of chronic hepatitis C...
  21. ncbi Clinical implications of hepatitis C viral kinetics
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt a M, Germany
    J Hepatol 31:61-4. 1999
    ....
  22. ncbi A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Hepatology 29:1280-7. 1999
    ..In conclusion, antiviral activity of rHuIL-12 in patients with chronic hepatitis C does not appear advantageous in comparison with other currently available treatments...
  23. ncbi What is (cost) effective in patients with chronic hepatitis C virus infection?
    S Zeuzem
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt aM, Germany
    Eur J Gastroenterol Hepatol 13:473-6. 2001
    ..g. by long-acting pegylated interferons), will have new impact on antiviral efficacy and cost effectiveness...
  24. ncbi Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt a M, Germany
    Hepatology 32:835-41. 2000
    ..In conclusion, combination therapy IFN-alpha plus amantadine is as effective as IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C...
  25. ncbi Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome
    U Mihm
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt Main, Germany
    J Viral Hepat 17:217-21. 2010
    ..In conclusion, Ribavirin-induced mutagenesis did not increase RNase L cleavage sites (UU/UA dinucleotides) within the HCV NS3 or NS5B encoding regions...
  26. ncbi Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C
    G Teuber
    Medizinische Klinik II, , Frankfurt, Germany
    J Viral Hepat 8:276-83. 2001
    ....
  27. ncbi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Gastroenterology 120:1438-47. 2001
    ..The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon alpha2a...
  28. ncbi Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer
    J Raedle
    Second Department of Internal Medicine, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Ann Intern Med 135:566-76. 2001
    ..The Bethesda guidelines were established to identify patients with colorectal cancer who should be tested for microsatellite instability...
  29. ncbi Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b
    J Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    J Viral Hepat 19:120-7. 2012
    ..Sequential short-term dosing of boceprevir was not associated with accumulation of resistant variants but pre-existing variants may impair virologic response...
  30. ncbi Comparison of envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates
    M W Welker
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik 1, Frankfurt am Main, Germany
    J Viral Hepat 18:181-92. 2011
    ..The variability in the CD81 binding regions appeared to be independent from CD81 expression...
  31. ncbi Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy
    W P Hofmann
    Department of Internal Medicine I, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    J Viral Hepat 15:790-6. 2008
    ..Antiviral therapy leads to an on-treatment increase of BMD, which may last in those patients who achieve a sustained virological response...
  32. ncbi Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions
    M W Welker
    Medizinische Klinik1, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    J Chemother 22:205-11. 2010
    ..In conclusion, in daily practice sorafenib is safe and disease stabilization can be achieved in the majority of patients. However, intolerance to sorafenib can affect treatment adherence substantially...
  33. ncbi Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy
    C Sarrazin
    Medizinische Klinik II, , Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
    Virology 289:150-63. 2001
    ....
  34. ncbi Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C
    M Friedrich-Rust
    Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    J Viral Hepat 16:168-77. 2009
    ....
  35. ncbi Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease
    M Friedrich-Rust
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    Ultraschall Med 30:478-84. 2009
    ..The aim of the present study was to validate real-time elastography using the formulas calculated in previous studies and to compare the results to transient elastography and FibroTest for the noninvasive assessment of liver fibrosis...
  36. ncbi Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C
    Gerlinde Teuber
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590 Frankfurt M, Germany
    J Hepatol 39:606-13. 2003
    ..Efficacy and safety of interferon-alpha (IFN-alpha)/ribavirin retreatment with or without amantadine sulphate were evaluated in non-responders with chronic hepatitis C...
  37. ncbi Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a
    C Sarrazin
    Medizinische Klinik II, , 60590 Frankfurt am Main, Germany
    J Clin Microbiol 39:2850-5. 2001
    ....
  38. ncbi New developments in HCV therapy
    B Kronenberger
    Department of Internal Medicine 1, Hospital of the Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    J Viral Hepat 19:48-51. 2012
    ..Several studies have been initiated that combine different novel therapies, with and without interferon ?/ribavirin...
  39. ncbi Peri-hepatic lymphadenopathy in primary biliary cirrhosis reflects progression of the disease
    C F Dietrich
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, Germany
    Eur J Gastroenterol Hepatol 11:747-53. 1999
    ..We prospectively investigated the peri-hepatic lymph node volume in patients with primary biliary cirrhosis (PBC) and healthy controls to evaluate the correlation with histology, biochemical and immunological features...
  40. ncbi Interferon alfa down-regulates CD81 in patients with chronic hepatitis C
    B Kronenberger
    Medizinische Klinik II, , , Frankfurt am Main, Frankfurt am Main, Germany
    Hepatology 33:1518-26. 2001
    ..5 vs. 139.8 +/- 27.5 RFU; P =.057). In conclusion, IFN-alpha and ribavirin regulate CD81 expression in vitro and in vivo. CD81 expression correlates with HCV genotype and initial virologic response in patients with chronic hepatitis C...
  41. ncbi Characterization of the nuclear import of human MutLalpha
    A Brieger
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt a M, Germany
    Mol Carcinog 43:51-8. 2005
    ....
  42. ncbi Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection
    O Waidmann
    Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie, Klinikum der Goethe Universität, Frankfurt Main, Germany
    J Viral Hepat 19:e58-65. 2012
    ..Furthermore, serum miR-122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification...
  43. ncbi Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection
    O Schroder
    Department of Nuclear Medicine, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Nuklearmedizin 37:279-85. 1998
    ..The differentiation of HCC from liver metastasis or benign disorders by imaging studies based upon morphological aspects may be difficult...
  44. ncbi Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy
    C M Lange
    Department of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Aliment Pharmacol Ther 32:14-28. 2010
    ..Novel, directly acting anti-viral agents, also named 'specifically targeted anti-viral therapy for hepatitis C' (STAT-C) compounds, are currently under development...
  45. ncbi 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection
    B Braden
    Medical Department II, University Hospital, Frankfurt Main, Germany
    Aliment Pharmacol Ther 21:179-85. 2005
    ..The 13C-methacetin breath test enables the quantitative evaluation of the cytochrome P450-dependent liver function...
  46. ncbi [Hypertransaminasaemia and impaired liver function in a patient with oligosymptomatic celiac disease]
    W P Hofmann
    Medizinische Klinik II, , Frankfurt/Main, Germany
    Z Gastroenterol 39:1027-32. 2001
    ..Serum aminotransferase levels normalized within 6 months. The clinical course demonstrates involvement of the liver in patients with celiac disease...
  47. ncbi Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease
    J Trojan
    Second Department of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    J Invest Dermatol 117:1650-3. 2001
    ..In conclusion, our data demonstrate that a PTEN splicing site mutation causes activation of a cryptic splice site, which results in aberrant transcripts...
  48. ncbi [44-year-old patient with fulminant liver failure]
    A Kerber
    Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt
    Internist (Berl) 44:1301-7. 2003
    ..The case represents the yet oldest patient reported with an acute manifestation of Wilson's disease...
  49. ncbi Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis
    M Friedrich-Rust
    Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany
    J Viral Hepat 19:e212-9. 2012
    ..91 for the diagnosis of severe fibrosis (F ? 3), and 0.93 for the diagnosis of cirrhosis. ARFI can be performed with good diagnostic accuracy for the noninvasive staging of liver fibrosis...
  50. ncbi Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1
    A Piiper
    Department of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany
    Mol Pharmacol 58:608-13. 2000
    ....
  51. ncbi [Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests]
    W P Hofmann
    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Z Gastroenterol 46:1283-9. 2008
    ..Besides other dynamic tests, the indocyanine green (ICG) clearance and the monoethylglycinxylid (MEGX) clearance tests have been satisfactorily evaluated...
  52. ncbi [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients]
    M von Wagner
    Medizinische Klinik I, Johann Wolfgang Goethe Universitat Frankfurt, Frankfurt a M, Germany
    Dtsch Med Wochenschr 134:255-8. 2009
    ..In case of bone marrow transplantation prophylaxis with nucleos(t)idanalogue has to be initiated before onset of treatment if anti-HBc is detectable, independent from HBsAg result...
  53. ncbi A de novo deletion of chromosome 5q causing familial adenomatous polyposis, dysmorphic features, and mild mental retardation
    J Raedle
    2nd Department of Internal Medicine and Institute of Human Genetics, University of Frankfurt/Main, Frankfurt am Main, Germany
    Am J Gastroenterol 96:3016-20. 2001
    ..If the deletion encompasses the APC gene, these patients are at high risk of developing FAP and associated complications...
  54. ncbi Hepatitis C viral kinetic models
    E Herrmann
    Department of Medicine, Saarland University Hospital, Germany
    Cell Death Differ 10:S7-8. 2003
  55. ncbi [Clinical aspects of liver cirrhoses and its complications and diagnostic problems]
    M Huber
    Medizinische Klinik II, Zentrum der Inneren Medizin, , Theodor-Stern-Kai 7, 60590 Frankfurt
    Radiologe 41:840-51. 2001
    ..Therapeutic management should mainly focus on the treatment of the underlying chronic liver disease in a precirrhotic stage. In the case of cirrhosis, prevention and treatment of complications are clinically most important...
  56. ncbi TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment
    G Teuber
    Medizinische Klinik II, , Frankfurt, Germany
    Z Gastroenterol 40:487-95. 2002
    ..This may offer an explanation for the unsatisfactory clinical efficiency of the substance...
  57. ncbi [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]
    T J Vogl
    Institut für Diagnostische und Interventionelle Radiologie, J W Goethe Universitat, Frankfurt
    Rofo 179:1113-26. 2007
    ..The local tumor response reaches up to 88% and the bleeding control is from 83 to 100%. CONCLUSION: TACE is a potentially curative, palliative, neoadjuvant, bridging and symptomatic therapy option for local and diffuse HCC...
  58. ncbi Subcellular distribution and function of Rab3A-D in pancreatic acinar AR42J cells
    A Piiper
    Department of Medicine II, University of Frankfurt Main, Frankfurt, 60590, Germany
    Biochem Biophys Res Commun 287:746-51. 2001
    ..In conclusion, our data indicate that the different Rab3 proteins show distinct subcellular distribution, suggesting different impact on exocrine secretory response in dexamethasone-differentiated AR42J cells...
  59. ncbi Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer
    J Raedle
    Medizinische Klinik II, Klinikum der J W Goethe Universitat, Frankfurt Main, Germany
    Z Gastroenterol 40:561-8. 2002
    ..However, the final diagnosis of HNPCC can only be established by detection of pathogenic germline mutations within the DNA mismatch repair genes...
  60. ncbi [Diagnostic imaging in liver cirrhosis]
    R M Hammerstingl
    Institut für Diagnostische und Interventionelle Radiologie, Johann Wolfgang Goethe Universitat, ZRAD Haus 23 A, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Radiologe 41:852-67. 2001
    ..This technique is the optimal protocol for diagnostic imaging in patients suffering from liver cirrhosis and the method of choice to reach the final diagnosis...
  61. ncbi Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid
    D Faust
    2nd Department of Internal Medicine and Gastroenterology, Johann Wolfgang Goethe-University, Frankfurt, Germany
    Z Gastroenterol 41:255-8. 2003
    ..Based on this case, it may be concluded that treatment with ursodeoxycholic acid might be beneficial in patients with NRHL and progression to liver insufficiency...
  62. ncbi Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection
    T Konrad
    Department of Internal Medicine and ndash I, Research Group for Clinical Physiology and Transplantation Physiology, J W Goethe University, Frankfurt a M, Germany
    Digestion 62:52-9. 2000
    ....
  63. ncbi Real-time elastography and contrast-enhanced ultrasound for the assessment of thyroid nodules
    M Friedrich-Rust
    Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany
    Exp Clin Endocrinol Diabetes 118:602-9. 2010
    ..The aim of the present study was to evaluate real-time elastography (RTE) and contrast-enhanced ultrasound with Sonovue (CEUS) for the differentiation of benign and malignant thyroid nodules...
  64. ncbi Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope
    J G Albert
    Department of Medicine I, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    Endoscopy 43:1004-9. 2011
    ..This technique should only be performed using CO2 insufflation...
  65. ncbi MUTYH hotspot mutations in unselected colonoscopy patients
    M Casper
    Department of Medicine II, Saarland University Medical Centre, Homburg, Germany
    Colorectal Dis 14:e238-44. 2012
    ..Y179C and p.G396D account for the majority of pathogenic variants of MUTYH in Caucasians. Our aim was to evaluate the prevalence of MUTYH mutations in a prospective cohort of unselected patients with different colorectal diseases...
  66. ncbi [Transient elastography (FibroScan) for the non-invasive assessment of liver fibrosis: current status and perspectives]
    M Friedrich-Rust
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Z Gastroenterol 45:387-94. 2007
    ..In addition, several studies have shown, that the FibroScan can be applied to estimate the risk of complications associated with liver cirrhosis...
  67. ncbi Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study
    I Blumenstein
    First Department of Internal Medicine, Division of Gastroenterology, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    J Crohns Colitis 5:203-10. 2011
    ..The aim of the present study was to evaluate gender-related differences in the treatment of a distinct IBD patient population treated in the Rhein-Main region, Germany...
  68. ncbi Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants
    A Brieger
    Medizinische Klinik II, , Frankfurt, Germany
    Gut 51:677-84. 2002
    ..This method is applicable for the functional definition of mutations in hMLH1 and hMSH2 genes observed in patients with suspected HNPCC...
  69. ncbi Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells
    U F Mondorf
    Department of Medicine, Division of Nephrology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    FEBS Lett 472:129-32. 2000
    ..In conclusion, our data show that Ang II-induced activation of mitogenic signalling cascade in human mesangial cells involves ligand-independent activation of the PDGFR, but not of the coexpressed EGFR...
  70. ncbi [Magnetic resonance cholangiopancreatography (MRCP) from a radiological and gastroenterological perspective]
    T J Vogl
    Institut für Diagnostische und Interventionelle Radiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Dtsch Med Wochenschr 134:1011-4. 2009
    ..MRCP is integrated in the preinterventional concept for performing invasive endoscopic retrograde cholangiopancreatography (ERCP) and for follow-up post intervention and for diagnosing complications...
  71. ncbi Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Matthias M Dollinger
    Department of Medicine I, Martin Luther University Halle Wittenberg, Germany
    BMC Cancer 10:457. 2010
    ..The aim of this study was to assess the efficacy of thymostimulin in a phase III trial...
  72. ncbi Expression and release of IL-18 binding protein in response to IFN-gamma
    J Paulukat
    Pharmazentrum Frankfurt and Second Department of Medicine, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    J Immunol 167:7038-43. 2001
    ..Down-regulation of IL-18BPa by sodium butyrate suggests that reinforcement of local IL-18 activity may contribute to actions of this short-chain fatty acid in the colonic microenvironment...
  73. ncbi Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    Stefan Zeuzem
    Department of Internal Medicine II, Saarland University Hospital, Homburg Saar, Germany
    Ann Intern Med 140:370-81. 2004
    ..This article reviews the data on interferon-based therapies among patients with lower chances for sustained virologic response and discusses the potential of the new pegylated interferons...
  74. ncbi Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:1359-67. 2003
    ....
  75. ncbi Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  76. ncbi Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  77. ncbi Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
    Michael von Wagner
    Johann Wolfgang Goethe Universitat, Frankfurt, Main, Germany
    Hepatology 48:1404-11. 2008
    ..CONCLUSION: In this large placebo-controlled multicenter study, amantadine even at a dose of 400 mg/day did not improve virological response rates of peginterferon alfa-2a and ribavirin in patients with chronic genotype HCV-1 infection...
  78. ncbi Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
    ..However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response...
  79. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  80. ncbi Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
    Huub C Gelderblom
    Department of Gastroenterology and Hepatology, AMC Liver Center, Homburg Saar, Germany
    Scand J Gastroenterol 43:1122-7. 2008
    ..4A protease inhibitor telaprevir (VX-950), with or without peginterferon alfa-2a (Peg-IFN)...
  81. ncbi Dynamics of hepatitis C virus infection
    Stefan Zeuzem
    Department of Medicine, University Hospital Homburg/Saar, Germany
    Ann Hepatol 1:56-63. 2002
    ..This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase...
  82. ncbi Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C
    Ulrike Mihm
    , , Kirrberger Strasse, D-66421 Homburg/Saar, Germany
    J Hepatol 40:845-52. 2004
    ..Thus, the conclusion from in vitro studies that the upregulation of interleukin-8 by the hepatitis C virus contributes to the inhibition of the antiviral actions of interferon-alpha may also be applicable in vivo...
  83. ncbi Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells
    Albrecht Piiper
    Department of Internal Medicine and Institute for Biochemistry II, Johann Wolfgang Goethe University, D 60590 Frankfurt, Germany
    J Biol Chem 277:43623-30. 2002
    ....
  84. ncbi Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, , Homburg/Saar, Germany
    Hepatology 37:1351-8. 2003
    ..This finding suggests that combination treatment leads to a better restoration of the patient's immune response...
  85. ncbi Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C
    Jens Rasenack
    Klinikum der Albert Ludwigs Universität, Freiburg, Germany
    Pharmacoeconomics 21:341-9. 2003
    ..Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a...
  86. ncbi Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system
    Joerg Trojan
    Second Department of Medicine, Johann Wolfgang Goethe University, Frankfurt a M, Germany
    Gastroenterology 122:211-9. 2002
    ..To date, functional analysis of missense mutations has been performed primarily in Saccharomyces cerevisiae. The aim of this study was to examine the biochemical properties of hMLH1 protein variants in a human expression system...
  87. ncbi Viral dynamics in chronic hepatitis B patients during lamivudine therapy
    Lonieke M M Wolters
    Department of Hepatogastroenterology, University Hospital Rotterdam, The Netherlands
    Liver 22:121-6. 2002
    ..The bi-phasic model as described by Neumann et al. in combination with frequent blood sampling provides the most accurate fit and can be used to compare new nucleoside analogue profiles to lamivudine therapy...
  88. ncbi Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  89. ncbi Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    Stefan Zeuzem
    Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Hepatol 44:97-103. 2006
    ..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
  90. ncbi Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C
    Markus Cornberg
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D-30625 Hannover, Germany
    J Hepatol 37:843-7. 2002
    ..These data suggest that inhibition of the IMPDH seems not to be the major mechanism of ribavirin in enhancing the antiviral effect of interferon alfa in chronic hepatitis C...
  91. ncbi Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon
    Albrecht Piiper
    Department of Internal Medicine II, University of the Saarland, D 66421 Homburg Saar, Germany
    J Biol Chem 278:7065-72. 2003
    ....
  92. ncbi Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    Michael von Wagner
    , Homburg/Saar, Germany
    Gastroenterology 129:522-7. 2005
    ..In patients infected by HCV-3 (high viral load), longer treatment may be necessary...
  93. ncbi Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor
    Albrecht Piiper
    Department of Internal Medicine, University of Saarland, D 66421, Homburg Saar, Germany
    Biochem Biophys Res Commun 301:848-54. 2003
    ..While PKA may directly phosphorylate the EGFR on serine residues, PKA-induced tyrosine phosphorylation of the EGFR occurs by an indirect mechanism...
  94. ncbi Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, , Campus Virchow-Klinikum, , Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  95. ncbi Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...
  96. ncbi Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  97. ncbi Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
    Joseph J Y Sung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, People s Republic of China
    J Hepatol 48:728-35. 2008
    ..We aimed to evaluate nucleoside/nucleotide combination therapy in treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB)...
  98. ncbi IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  99. ncbi Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, , , Sweden
    J Infect Dis 194:895-903. 2006
    ..CONCLUSION: Baseline IP-10 levels are predictive of the response to HCV treatment...
  100. ncbi Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
    Martijn J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    Hepatology 44:721-7. 2006
    ..Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult...